Recent Updates
Recently added Catalysts
IBRX Positive Sentiment

New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ImmunityBio announced results from a survey of military personnel and veterans with non-muscle invasive bladder cancer. The survey revealed that 53% were diagnosed at age 50 or younger, with a mean diagnosis age of 51.7 years. Additionally, 63% of respondents faced barriers to treatment, highlighting significant challenges in care access.

Market Sentiment Analysis

POSITIVE FACTORS

  • 53% diagnosed at age 50 or younger indicates early detection.
  • Survey highlights awareness of NMIBC among veterans.
  • Identifies barriers to care, prompting potential improvements.

CONCERNS & RISKS

  • 63% reported barriers or challenges to receiving treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
9.3%
average across 5 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
PD-L1 t-haNK
Phase 1 · Locally Advanced Solid Tumor

Full Press Release Details

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer (NMIBC). The survey, conducted by The Harris Poll on behalf of ImmunityBio, found that 53% of respondents were diagnosed by age 50 and 63% reported barriers or challenges to receiving treatment. Respondents reported a mean age of 51.7 years at diagnosis (m

Frequently Asked Questions

What percentage of veterans were diagnosed by age 50?

53% of respondents were diagnosed by age 50 or younger.

What challenges did veterans face regarding treatment?

63% reported barriers or challenges to receiving treatment.

What was the mean age at diagnosis for NMIBC?

The mean age at diagnosis was 51.7 years.

Who conducted the survey on NMIBC?

The survey was conducted by The Harris Poll for ImmunityBio.

ShareAdd on Google
Tags: IBRX ImmunityBio NMIBC military veterans barriers to care Harris Poll
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$334M liquidity · $25M/mo burn
~13 mo
Low dilution risk
Lead asset
PD-L1 t-haNKPhase 1
Locally Advanced Solid Tumor →

Catalyst track record

+29%
best trade around IBRX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IBRX.

See every catalyst's timing & PoA →